Respiratory and Immunology is one of AstraZeneca’s three priority therapy areas and is a key growth driver for the Company.
We have a longstanding research and development capability in Immunology and combining common pathways and underlying disease drivers across Respiratory and Immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
Our growing presence in Immunology is focused on five mid- to late-stage franchises with multi-disease potential. The disease areas we’re targeting include rheumatology (including type 1 interferon-driven diseases such as lupus), dermatology, gastroenterology diseases and systemic eosinophilic-driven diseases. Our ambition is to achieve disease modification and durable remission in these diseases for millions of patients worldwide.
With our return to growth, we are in a strong position to competitively commercialise our assets across both Respiratory and Immunology disease areas, building on our strong capability to deliver successful launches in specialty care.
Our focus on Immunology is about following the science. We have a high-performing Respiratory portfolio with some of the industry’s leading treatment options for asthma, COPD and other airway diseases. Based on our strong belief in following the science and our commitment to patients, we are now exploring the possibility for some of these same molecules - along with several new molecules - to address significant unmet need within Immunology.
We are widening our focus to include both Respiratory and Immunology by leveraging existing and new talent alongside our specialty experience to deliver for respiratory and immunology patients. We see this as an opportunity to do more for more patients with debilitating disease who have very little treatment options.
